Atlas Trials

A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies

Clinical trial NCT02329847 · COMPLETED

Trial details

NCT number
NCT02329847
Sponsor
Janssen Research & Development, LLC
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Hematologic Neoplasms
Start date
2015-03-11
Primary completion
2022-02-09
Enrollment
144

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.